Familial hemiplegic migraine type 3 (FHM3) is a severe autosomal dominant migraine disorder caused by mutations in the voltagegated sodium channel Na V1.1 encoded by SCN1A. We determined the functional consequences of three mutations linked to FHM3 (L263V, Q1489K, and L1649Q) in an effort to identify molecular defects that underlie this inherited migraine disorder. Only L263V and Q1489K generated quantifiable sodium currents when coexpressed in tsA201 cells with the human ␤ 1 and ␤ 2 accessory subunits. The third mutant, L1649Q, failed to generate measurable whole-cell current because of markedly reduced cell surface expression. Compared to WT-Na V1.1, Q1489K exhibited increased persistent current but also enhanced entry into slow inactivation as well as delayed recovery from fast and slow inactivation, thus resulting in a predominantly loss-of-function phenotype further demonstrated by a greater loss of channel availability during repetitive stimulation. In contrast, L263V exhibited gain-offunction features, including delayed entry into, as well as accelerated recovery from, fast inactivation; depolarizing shifts in the steady-state voltage dependence of fast and slow inactivation; increased persistent current; and delayed entry into slow inactivation. Notably, the two mutations (Q1489K and L1649Q) that exhibited partial or complete loss of function are linked to typical FHM, whereas the gain-of-function mutation L263V occurred in a family having both FHM and a high incidence of generalized epilepsy. We infer from these data that a complex spectrum of Na V1.1 defects can cause FHM3. Our results also emphasize the complex relationship between migraine and epilepsy and provide further evidence that both disorders may share common molecular mechanisms.
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epilepsy ͉ SCN1A ͉ Na V 1.1 ͉ FHM3 M igraine is a common paroxysmal neurovascular disorder with a lifetime prevalence of 14-18% worldwide (1) . An estimated 30 million migraine sufferers in the United States alone represent a significant public health burden. Genetic factors are important determinants of migraine susceptibility, and understanding the molecular basis of rare monogenetic migraine syndromes may help unravel the pathophysiology of more common forms of migraine (2) .
Familial hemiplegic migraine (FHM) is a rare autosomal dominant form of migraine with aura (MA) characterized by the presence of transient motor weakness and other aura symptoms, such as visual and speech disturbances (3). FHM probands also have an increased incidence of typical MA attacks, suggesting that FHM and MA may exhibit shared pathophysiology (4) . Mutations in three genes encoding distinct ion-transporting proteins have been linked to FHM. FHM1 is caused by mutations in CACNA1A encoding the pore-forming ␣ 1 -subunit of the neuronal calcium channel, Ca V 2.1 (5), whereas mutations in ATP1A2 encoding the catalytic ␣ 2 -subunit of the glial Na ϩ /K ϩ -ATPase in adult brain cause FHM2 (6) . Two missense mutations (Q1489K and L1649Q) in SCN1A encoding the pore-forming ␣-subunit of the voltagegated sodium channel Na V 1.1 have been linked to FHM3 (7, 8) . Corresponding mutations engineered into the paralogous cardiac Na V 1.5 were observed to cause significant functional disturbances, further supporting the pathogenicity of these alleles. At the time, attempts to study the functional consequences in the human Na V 1.1 channel were not successful.
SCN1A mutations have been previously associated with various genetic childhood epilepsies ranging in clinical severity from benign (generalized epilepsy with febrile seizures plus) to debilitating (severe myoclonic epilepsy of infancy). Functional studies of epilepsy-associated Na V 1.1 mutants have demonstrated either functional channels with altered biophysical properties or nonfunctional channels (9) (10) (11) (12) (13) (14) (15) . Among the subset of missense mutations characterized, there are no general correlations between mutation location in the sodium channel protein and the functional consequences. Therefore, prediction of the functional effects of FHM3 mutations is not feasible without direct experimental evidence.
Here we determined the molecular basis of FHM3 by examining the biophysical or biochemical properties of three FHM3 mutants engineered in a recombinant human Na V 1.1 channel. We studied two previously published mutations (Q1489K and L1649Q) as well as a third mutation (L263V) recently identified in an FHM family in which the majority of mutation carriers also have epilepsy (42) . Our data revealed that FHM3 is associated with a wide range of Na V 1.1 defects, suggesting that multiple molecular mechanisms may underlie FHM3. Furthermore, specific biophysical features observed for L263V may also explain the higher prevalence of epilepsy associated with this mutation.
Results
In this study, we determined the functional consequences of three FHM3 mutations engineered in human Na V 1.1 to ascertain the molecular defects underlying this disorder. Two of the FHM3 mutations we studied were reported previously (Q1489K and L1649Q) (7, 8) . Q1489K introduces a positive charge 11 residues N-terminal to the Ile-Phe-Met motif within the cytoplasmic linker between domain III (DIII) and DIV, a structure essential for fast inactivation (16, 17) . L1649Q introduces a polar residue adjacent to a conserved arginine (Arg-1648) in the S4 voltage sensor segment of DIV, a residue mutated in genetic epilepsy syndromes (12, 14, 18, 19) . The third FHM3 mutation, L263V, affects a conserved residue in the D1/S5 segment and was recently identified in a Portuguese family in which epilepsy co-occurred in three of five mutations carriers with hemiplegic migraine (42) .
Transient coexpression of each FHM3 mutation with the human sodium channel ␤ 1 and ␤ 2 accessory subunits in tsA201 cells resulted in measurable voltage-sensitive sodium currents for L263V and Q1489K, but not L1649Q. Fig. 1 illustrates representative whole-cell current traces recorded from cells expressing WTNa V 1.1, L263V, Q1489K, or L1649Q. Repeated attempts to record from cells transfected with L1649Q revealed consistently small sodium currents (Fig. 1D) . However, only 1 of 46 cells expressing L1649Q exhibited whole-cell peak currents of Ͼ600 pA, and we could not satisfactorily exclude a contribution of endogenous channels to these recordings. Thus, we considered L1649Q mutant channels as nonfunctional.
Impaired Activation and Inactivation for L263V and Q1489K. We determined the biophysical properties of the two functional mutants L263V and Q1489K. Fig. 2A illustrates that there were no significant differences in the peak current density for either mutant at any test potential. Both L263V and Q1489K exhibited trends toward activating at more negative membrane potentials (Fig. 2B) , but neither shift in activation, V 1/2 , was statistically significant [supporting information (SI) Table S1 ]. The voltage dependence of fast inactivation was explored by measuring channel availability at Ϫ10 mV after a depolarizing 100-ms prepulse to various test potentials. Fig. 2C illustrates that L263V exhibits a ϩ8 mV depolarizing shift in the V 1/2 of steady-state inactivation compared to WT-Na V 1.1, suggesting that L263V resists entry into the fast inactivated state (Table S1 ). Moreover, examining the overlap in the activation (Fig. 2B ) and inactivation ( Fig. 2C ) predicts increased ''window current'' for L263V as compared to WT-Na V 1.1.
L263V and Q1489K exhibited divergent effects on the time course of recovery from fast inactivation compared to WT-Na V 1.1 (Fig. 2D ). L263V exhibited accelerated recovery from inactivation as indicated by a significantly smaller time constant representing the faster component, f (Table S1 ). In contrast, Q1489K exhibited slower recovery from inactivation compared to WT-Na V 1.1 explained by a larger time constant, s , and increased fractional amplitude, A s , representing the slower component (Table S1 ).
Abnormal L263V gating is also apparent in the kinetics of the whole-cell current traces. Fig. 3A illustrates a representative wholecell current recorded in response to a voltage step from Ϫ120 to Ϫ10 mV for WT-Na V 1.1 and L263V. This mutant exhibited delayed entry into fast inactivation, as evidenced by a broadening in the decay phase of the whole-cell current trace. The time constants corresponding to the fast component of the whole-cell current decay were significantly larger for L263V compared to WT-Na V 1.1 at every test potential ( Fig. 3B and Table S2 ). Time to peak current was also delayed in cells expressing L263V (Fig. 3C ), and this phenomenon could reflect the slower inactivation kinetics or an independent effect on activation. There was no significant defect in activation or inactivation kinetics observed for Q1489K.
Many epilepsy-associated Na V 1.1 mutants have been shown to exhibit a significantly increased persistent current due to impaired inactivation (11) (12) (13) (14) (15) . Fig. 4 illustrates representative TTX-sensitive, whole-cell currents for WT-Na V 1.1, L263V, and Q1489K recorded in response to a 200-ms, depolarizing voltage step to Ϫ10 mV. Both L263V and Q1489K exhibit significantly increased persistent current levels compared to WT-Na V 1.1 (WT-Na V 1.1, 0.40 Ϯ 0.06%, n ϭ 5; L263V, 1.37 Ϯ 0.22%, n ϭ 6, P Ͻ 0.01; Q1489K, 1.48 Ϯ 0.19%, n ϭ 7, P Ͻ 0.01).
Divergent Effects on Slow Inactivation. Na V 1.1 channels exhibit slow inactivation, a process distinct from fast inactivation that may regulate channel availability during sustained membrane depolarizations or repetitive neuronal firing. We tested L263V and Q1489K for defects in slow inactivation by using the voltage protocols illustrated in Fig. 5 that largely eliminate the contribution of fast inactivation to channel activity. Compared to WT-Na V 1.1, L263V displayed a delay in the onset (Fig. 5A ) and a ϩ13-mV depolarizing shift in the V 1/2 of steady-state slow inactivation (Fig. 5B) . These findings predict that, similar to fast inactivation, L263V resists entry into slow inactivated states. In contrast, Q1489K entered slow inactivation more rapidly compared to WT-Na V 1.1 (Fig. 5A ), but there was no difference in voltage dependence. Both L263V and Q1489K exhibited small but significant effects on recovery from slow inactivation compared to WT-Na V 1.1 ( Fig. 5C and Table S3) , and these effects represent a distinct channel abnormality from the altered recovery from fast inactivation illustrated in Fig. 2D . These findings indicate that L263V and Q1489K exhibit divergent effects on slow inactivation that may inf luence steady-state channel availability.
To test channel availability of WT or mutant Na V 1.1 channels during repetitive stimulation (use-dependence), we measured whole-cell peak current amplitudes during a train of 100 depolarizing voltage steps to 0 mV at various frequencies. The peak whole-cell current measured in response to the 100th voltage step was normalized by the peak current obtained from the first step and plotted against the stimulation frequency (Fig. 6 ). L263V exhibited significantly greater channel availability for pulse train frequencies 100-140 Hz. In contrast, Q1489K displayed significantly lower channel availability for pulse train frequencies 35-140 Hz. At a stimulation frequency of 100 Hz, the residual availability of WTNa V 1.1 channels at the 100th pulse was 0.56 Ϯ 0.07 (n ϭ 6) compared to 0.71 Ϯ 0.02 (n ϭ 10, P Ͻ 0.05) for L263V and 0.33 Ϯ 0.03, (n ϭ 7, P Ͻ 0.001) for Q1489K. Fig. 6 also illustrates the use-dependent behavior of an epilepsy-associated mutation (R1648H) that exhibits a level of residual availability (0.74 Ϯ 0.02, n ϭ 10, P Ͻ 0.01 as compared to WT) very similar to L263V, the FHM3 mutation associated with a high prevalence of seizures.
L1649Q Has Reduced Cell Surface Expression. The FHM3 mutant L1649Q failed to generate quantifiable whole-cell sodium currents when transiently expressed in tsA201 cells (Fig. 1) . To determine whether L1649Q non-function was due to impaired trafficking of channels to the plasma membrane, we used cell-surface biotinylation coupled with Western blot analysis. Fig. 7A illustrates a representative experiment demonstrating that cells transfected with either WT-Na V 1.1 or L1649Q exhibit similar levels of total protein expression (Fig. 7A Left) . However, L1649Q channels are not expressed at the cell surface to the same extent as WT-Na V 1.1 (Fig.  7A Right) . The magnitude of L1649Q cell surface expression was quantified by using densitometry and normalized by the intensity of the protein band in the total fraction. Averaged data from three independent experiments (Fig. 7B) illustrate that L1649Q (0.14 Ϯ 0.08, n ϭ 3, P Ͻ 0.01) exhibited a significantly lower level of cell surface expression compared to WT-Na V 1.1 (1.00 Ϯ 0.06, n ϭ 3). These data indicated that the lack of L1649Q whole-cell current was the direct result of a loss of L1649Q cell surface expression and most likely reflects impaired trafficking to the plasma membrane.
Discussion
We determined the functional consequences of three SCN1A mutations (L263V, Q1489K, and L1649Q) associated with FHM3 to understand the molecular defects underlying this inherited migraine syndrome. Our work demonstrated that FHM3 is associated with mutant Na V 1.1 channels exhibiting a broad range of abnormalities, including gain of function (L263V), predominant loss of function (Q1489K), or complete loss of function (L1649Q), suggesting that this neurological disorder can result from multiple molecular defects.
Two of the mutations (Q1489K and L1649Q) were reported previously (7, 8) , and these prior studies used a recombinant human cardiac sodium channel (Na V 1.5) to demonstrate functional aberrations caused by the mutations. Specifically, these experiments identified gain-of-function phenotypes, such as an accelerated recovery from fast inactivation observed for both mutants or impaired fast inactivation noted for a Na V 1.5 mutation equivalent to L1649Q. However, these data contrast considerably with our findings for human Na V 1.1, most likely because of intrinsic structural and functional differences between the two sodium channel isoforms (11, 20) . Therefore, we performed a comprehensive evaluation of these two FHM3 alleles in Na V 1.1. Furthermore, a third FHM3 mutation (L263V) was recently discovered that we were also able to study.
Functional Heterogeneity of FHM3 Mutations.
The most striking finding of our work was the diversity of molecular defects observed for the three FHM3 mutations. On one extreme L1649Q was nonfunctional, most likely because of its diminished trafficking to the plasma membrane. Defective trafficking of mutant sodium channels could be caused by intrinsic misfolding of the large ␣-subunit protein or through abnormal interactions with accessory subunits (10, 21) . Q1489K exhibits a mixture of functional defects including increased persistent current, more rapid onset of slow inactivation, and greater loss of channel availability during repetitive stimulation. From these observations, we deduced that Q1489K causes a predominantly loss-of-function phenotype. In contrast, L263V exhibited a constellation of biophysical abnormalities that predict increased sodium conductance and greater channel availability consistent with a gain-of-function mutation. Specifically, when compared to WT-Na V 1.1, L263V channels exhibited impaired fast and slow inactivation, increased persistent current, depolarized voltage dependence of both forms of inactivation, Table S1 .
accelerated recovery from fast inactivation, and greater channel availability during repetitive stimulation. Notably, greater channel availability during repetitive stimulation as seen for L263V also has been observed for various epilepsy-associated SCN1A mutations (Fig. 6) (15) . Perhaps this biophysical feature correlates with the unusually high prevalence of epilepsy observed in L263V mutation carriers. The coincidence of migraine with epilepsy suggests that these two neurological disorders may share common mechanisms in L263V mutation carriers.
Pathogenesis of FHM3.
Migraine is a complex neurovascular disorder. Headache is thought to originate from activation of the trigeminovascular system (i.e., the trigeminal innervation of cranial blood vessels and connections to the brainstem), whereas the aura is caused by cortical spreading depression (CSD), which is an initial increase in neuronal activity immediately followed by a refractory and long-lasting depression of activity that slowly propagates across the cortex (22, 23) . However, a detailed understanding of the primary trigger and underlying mechanisms for CSD remains unclear. Cellular studies with FHM mutants suggest a key role for increased extracellular glutamate and K ϩ (FHM1 and FHM2) for lowering the threshold of cortical neurons for CSD. CACNA1A mutations (FHM1) are thought to enhance presynaptic cortical glutamate release, whereas ATP1A2 mutations (FHM2) result in impaired clearance of K ϩ and glutamate form the synaptic cleft (24) . Genetically engineered knock-in mice carrying a pathogenic FHM1 mutation revealed gain-of-function effects with increased calcium influx and neurotransmitter release resulting in a reduced CSD threshold (25) , supporting the concept that the migrainous brain is hyperexcitable (26) . Whereas, Ca V 2.1 channels and ␣ 2 -containing Na ϩ /K ϩ -ATPase pumps are expressed in and around glutamatergic synapses, Na V 1.1 channels are expressed somatodendritically (27) (28) (29) (30) (31) and in the axonal initial segment (32) (33) (34) , where they may contribute to integrating incoming signals and controlling neuronal excitability. Therefore, the functional defects we observed for mutant Na V 1.1 channels may cause FHM3 by nonsynaptic mechanisms.
Recent work with two Na V 1.1 knock-out mouse models may offer valuable insight into how our data may integrate into this pathophysiological model of FHM. Loss of one Na V 1.1 allele in mice preferentially decreased the functioning of inhibitory GABAergic interneurons without effects on excitatory pyramidal neurons isolated from the hippocampus (32, 35) . In contrast, mice overexpressing a gain-of-function mutation in Na V 1.2 exhibit seizures that correlate with increased persistent current in hippocampal excitatory pyramidal neurons (36) . These findings suggest that loss of sodium channel activity disproportionately hinders functioning of inhibitory neurons, whereas gain-of-function mutations may Fig. 3 . L263V exhibits delayed whole-cell current kinetics. (A) Representative whole-cell sodium currents evoked by a voltage step to Ϫ10 mV and normalized to peak current for WT-Na V1.1 and L263V. (B) Decay phase of the whole-cell sodium current was fit with a two-exponential equation, and the inactivation time constants representing the faster component ( f) for WT-NaV1.1 (ᮀ), L263V (), and Q1489K (OE) are plotted against the test potential. Fit parameters are provided in Table S2 . (C) Time to peak sodium current for WT-Na V1.1 (ᮀ), L263V (), and Q1489K (OE) plotted against the test potential. L263V exhibited a significantly delayed peak current compared to WT-Na V1.1. Significant differences from WT-Na V1.1 are indicated as follows: * , P Ͻ 0.05; ** , P Ͻ 0.001. predominantly influence excitatory neurons. The basis for these differential effects may lie in intrinsic differences at the neuron level, such as in safety factor for action potential generation, sodium channel density, and dendritic morphology. For example, inhibitory neurons have higher sodium channel density, exhibit lower action potential thresholds, and decreased frequency attenuation during high-intensity stimulation (37) . These neurophysiological attributes are likely critical for inhibitory neurons to exert their influence on cortical output. We can speculate that the reduced threshold for CSD in FHM3 is the final common pathway resulting from the differential impact of gain-or loss-of-function Na V 1.1 mutations on these neuronal subpopulations.
Defining the role of mutant Na V 1.1 in FHM3 is hampered by the lack of specific information concerning the expression pattern and functional contributions of this channel to cortical neuronal excitability. Moreover, in contrast to Ca V 2.1 and ␣ 2 -containing Na ϩ / K ϩ -ATPase, Na V 1.1 is expressed at sites physically distant from the Time-dependent entry into slow inactivation was examined by using a two-pulse protocol consisting of a variable length inactivation pulse to Ϫ10 mV followed by a test pulse at Ϫ10 mV. Effects of fast inactivation were minimized by using a 50-ms interpulse step to Ϫ120 mV. (B) Voltage-dependent entry into slow inactivation was examined by using a two-pulse protocol consisting of a 30-s conditioning pulse at various potentials followed by a test pulse at Ϫ10 mV. Effects of fast inactivation were minimized by using a 50-ms interpulse step to Ϫ120 mV. (C) Time-dependent recovery from slow inactivation was examined by using a two-pulse protocol consisting of a 30-s inactivation pulse to Ϫ10 mV followed by a variable length interpulse step to Ϫ120 mV and a test pulse to Ϫ10 mV. Data were fit by using either a two exponential (A and C) or Boltzmann (B) equation; fit parameters are provided in Table S3 . Fig. 6 . Use-dependent effects on channel availability for WT and mutant Na V1.1. Use-dependent channel availability was assessed by stimulating cells with depolarizing pulse trains (100 pulses, 5 ms, 0 mV) from a holding potential of Ϫ120 mV at the indicated frequencies. The residual sodium current (100th pulse) was normalized to the first pulse for each stimulation train. A recovery period (15 s, Ϫ120 mV) followed each pulse train. Significant differences from WT-Na V1.1 are indicated as follows: * , P Ͻ 0.05; ** , P Ͻ 0.01; *** , P Ͻ 0.001. glutamatergic synapse. Therefore, we anticipate the pathophysiology of mutant Na V 1.1 in FHM3 to reflect a more complex mechanism. Genetically engineered animal models expressing mutant Na V 1.1 channels in specific neuronal subpopulations will be invaluable to elucidate the role of dysfunctional Na V 1.1 in FHM3.
Materials and Methods
Mutagenesis and Expression of Human NaV1.1 cDNA. Mutagenesis of recombinant human NaV1.1 was performed by using PCR as previously described (11, 14) . Due to a tendency of Na V 1.1 cDNA to spontaneously mutate in bacterial culture, we propagated clones in Stbl2 host cells (Invitrogen) at 30°C and then sequenced the complete ORF of each construct to exclude polymerase-induced errors and inadvertent mutations. A minimum of two recombinant clones of each mutation were evaluated functionally. Heterologous expression of WT and mutant Na V1.1 channels was performed in human tsA201 cells (HEK293 cells stably expressing the simian virus 40 large T antigen). Cells were grown in Dulbecco modified Eagle's medium supplemented with 10% FBS, 2 mM L-glutamine, and 50 units/ml penicillin/50 g/ml streptomycin in a humidified, 5% CO2 atmosphere at 37°C. Only low-passage-number (Ͻ15) cells were used. Expression of NaV1.1, ␤1, and ␤2 was achieved with transient transfection by using Qiagen Superfect reagent (5.5 g of DNA was transfected at a plasmid mass ratio of 7:1:1 for ␣ 1 /␤ 1 /␤ 2 ). The human ␤1 and ␤2 cDNAs were cloned into plasmids containing the marker genes DsRed (DsRed-IRES2-h␤ 1) or EGFP (EGFP-IRES2-h␤2) along with an internal ribosome entry site. Unless otherwise noted, all reagents were purchased from Sigma-Aldrich.
Electrophysiology. Whole-cell voltage-clamp recordings were used to measure the biophysical properties of WT and mutant NaV1.1 channels, as previously described (12, 14) . Sodium channel currents were recorded at room temperature (21-22°C), 24 -48 h after transfection. Additional experimental details are provided in SI Materials and Methods. Data analysis was performed by using Clampfit 9.2 (Axon Instruments), Excel 2002 (Microsoft), and OriginPro 7.0 (OriginLab) software. Results are presented as mean Ϯ SEM. Unless otherwise noted, statistical comparisons were made by using one-way ANOVA followed by a Tukey post hoc test in reference to WT-NaV1.1.
Cell Surface Biotinylation. Cell surface biotinylation was performed as described previously with minor modifications for NaV1.1 detection (38 -41) . WT-NaV1.1 and L1649Q were epitope-tagged with a triple FLAG tag (3XFLAG) on the C terminus to increase detection sensitivity. The presence of the 3XFLAG on WTNaV1.1 did not significantly affect the biophysical function of WT channels (data not shown). Membrane impermeant sulfo-NHS-biotin reagent (Pierce Biotechnology) was used to specifically isolate membrane proteins that are accessible to the extracellular solution. NaV1.1 was detected with primary antibodies directed against the FLAG epitope anti-FLAG M2 (mouse) at 1:15,000 (Sigma-Aldrich). Immunoreactive bands were visualized by using horseradish peroxidaseconjugated goat anti-mouse secondary antibody at 1:10,000 (Santa Cruz Biotechnology) directed against the primary antibody, ECL Plus (GE Healthcare BioSciences), and Hypersensitive ECL film detection. Densitometry of protein bands was used to quantitate protein levels (ImageJ software, National Institutes of Health). Normalization to the total was used to control for protein loading. Additional experimental details are provided in the SI Materials and Methods.
